Most importantly, c-Met+ CD8+ clones produced higher levels of effector molecules (e.g., IFN-γ and GrB) compared to their c-Met− CD8+ counterparts and exhibited significant specific lysis capacities against tumor cells. The gene discussed is CD8A; the disease is neoplasm.